359 related articles for article (PubMed ID: 31099654)
1. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
2. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
[TBL] [Abstract][Full Text] [Related]
3. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
Gondek LP; DeZern AE
Lancet Haematol; 2020 Jan; 7(1):e73-e81. PubMed ID: 31810765
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
Steensma DP
Curr Hematol Malig Rep; 2019 Dec; 14(6):536-542. PubMed ID: 31696381
[TBL] [Abstract][Full Text] [Related]
5. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
6. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
7. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Valent P
Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
9. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
10. When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?
Osman AEWG
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):399-404. PubMed ID: 34889436
[TBL] [Abstract][Full Text] [Related]
11. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
Weinberg OK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
[TBL] [Abstract][Full Text] [Related]
13. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
14. Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis.
Karner K; George TI; Patel JL
Ann Lab Med; 2019 Nov; 39(6):509-514. PubMed ID: 31240877
[TBL] [Abstract][Full Text] [Related]
15. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
16. How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide.
Xie Z; DeZern AE
NEJM Evid; 2023 May; 2(5):EVIDe2300053. PubMed ID: 38320009
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
[TBL] [Abstract][Full Text] [Related]
18. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
19. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
[TBL] [Abstract][Full Text] [Related]
20. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]